Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

627
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
627
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

674
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
674
Transcellular Transport of Solutes01:23

Transcellular Transport of Solutes

5.4K
Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
5.4K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.4K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early life elevations of methionine oxidation and ornithine track and predict cystic fibrosis structural lung disease.

ERJ open research·2025
Same author

Single cell transcriptional profiling of monocytes from asthma patients show a predisposition for an inflammatory response.

Cytotherapy·2025
Same author

Key inflammatory markers in bronchoalveolar lavage predict bronchiectasis progression in young children with CF.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2024
Same author

Nasal airway inflammatory responses and pathogen detection in infants with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Pulmonary exacerbations in early cystic fibrosis lung disease are marked by strong modulation of CD3 and PD-1 on luminal T cells.

Frontiers in immunology·2023
Same author

Diagnostic challenges in CFTR-related metabolic syndrome: Where the guidelines fall short.

Paediatric respiratory reviews·2023

Related Experiment Video

Updated: Apr 10, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K

Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.

Lokesh Guglani1

  • 1Division of Pulmonary Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, 3901 Beaubien St, Detroit, MI, 48201, USA, lguglani@med.wayne.edu.

Indian Journal of Pediatrics
|June 17, 2015
PubMed
Summary

Cystic fibrosis (CF) research has advanced significantly, transforming it from a childhood disease to a chronic condition managed with precision medicine. Mutation-specific therapies offer new hope and improved outcomes for patients.

More Related Videos

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
15:12

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae

Published on: May 10, 2014

15.1K
Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice
08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

8.3K

Related Experiment Videos

Last Updated: Apr 10, 2026

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K
Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae
15:12

Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein Expressed in Saccharomyces cerevisiae

Published on: May 10, 2014

15.1K
Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice
08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

8.3K

Area of Science:

  • Medical Genetics
  • Pulmonology
  • Pharmacogenomics

Background:

  • Cystic fibrosis (CF) has evolved from a pediatric illness to a chronic, life-limiting genetic disorder.
  • Advances in understanding CF pathogenesis and therapies have accelerated since the CF gene discovery in 1989.
  • Patient survival has extended into the fourth decade due to these developments.

Purpose of the Study:

  • To review recent breakthroughs in cystic fibrosis research.
  • To highlight the paradigm shift in CF management and patient outcomes.
  • To emphasize the role of precision medicine in treating CF.

Main Methods:

  • Literature review of recent advances in CF research.
  • Analysis of the impact of mutation-specific therapies.
  • Discussion of personalized medicine approaches in CF.

Main Results:

  • The development of mutation-specific therapies marks a new era of precision medicine for CF.
  • Personalized medicine approaches are reverting the basic defect in CF.
  • These advancements have significantly improved CF patient outcomes and management.

Conclusions:

  • Cystic fibrosis management has undergone a paradigm shift, moving towards personalized and precision medicine.
  • Mutation-specific therapies hold the potential to alter the natural history of CF.
  • CF treatment serves as a model for managing other chronic genetic disorders.